Kantonsspital St.Gallen

A multicenter, non-randomized, open-label phase 1b study to determine the maximum tolerated and recommended phase 2 dose of the ATR Inhibitor BAY 1895344 in combination with pembrolizumab and characterize its safety, tolerability, pharmacokinetics and preliminiary anti-tumor activity in patients with advanced solid tumors

Markus Joerger

abstract BAY-1895344 und Pembrolizumab bei ausgewählten Tumoren
mit genetischen Alterationen von ATM.
project partner Bayer
type of project clinical studies
status scheduled
start of project 2021
end of project 2022
study design Phase Ib
responsible person Prof. Dr. Markus J├Ârger